BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 10817557)

  • 1. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity.
    Weyand CM; Fulbright JW; Hunder GG; Evans JM; Goronzy JJ
    Arthritis Rheum; 2000 May; 43(5):1041-8. PubMed ID: 10817557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of a normal C-reactive protein with an elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis.
    Parikh M; Miller NR; Lee AG; Savino PJ; Vacarezza MN; Cornblath W; Eggenberger E; Antonio-Santos A; Golnik K; Kardon R; Wall M
    Ophthalmology; 2006 Oct; 113(10):1842-5. PubMed ID: 16884778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurence in a population-based study.
    Salvarani C; Hunder GG
    Arthritis Rheum; 2001 Apr; 45(2):140-5. PubMed ID: 11324777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term followup of patients with giant cell arteritis.
    García-Martínez A; Hernández-Rodríguez J; Espígol-Frigolé G; Prieto-González S; Butjosa M; Segarra M; Lozano E; Cid MC
    Arthritis Care Res (Hoboken); 2010 Jun; 62(6):835-41. PubMed ID: 20535794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study.
    Salvarani C; Cantini F; Niccoli L; Macchioni P; Consonni D; Bajocchi G; Vinceti M; Catanoso MG; Pulsatelli L; Meliconi R; Boiardi L
    Arthritis Rheum; 2005 Feb; 53(1):33-8. PubMed ID: 15696567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble interleukin 2 receptors in polymyalgia rheumatica/giant cell arteritis. Clinical and laboratory correlations.
    Salvarani C; Macchioni P; Boiardi L; Rossi F; Casadei Maldini M; Mancini R; Beltrandi E; Spacca C; Lodi L; Portioli I
    J Rheumatol; 1992 Jul; 19(7):1100-6. PubMed ID: 1512765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The erythrocyte sedimentation rate is associated with the development of visual complications in biopsy-proven giant cell arteritis.
    Lopez-Diaz MJ; Llorca J; Gonzalez-Juanatey C; Peña-Sagredo JL; Martin J; Gonzalez-Gay MA
    Semin Arthritis Rheum; 2008 Oct; 38(2):116-23. PubMed ID: 18221984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating CD8+ T cells in polymyalgia rheumatica and giant cell arteritis: a review.
    Martinez-Taboada VM; Blanco R; Fito C; Pacheco MJ; Delgado-Rodriguez M; Rodriguez-Valverde V
    Semin Arthritis Rheum; 2001 Feb; 30(4):257-71. PubMed ID: 11182026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silent, or masked, giant cell arteritis is associated with a strong inflammatory response and a benign short term course.
    Liozon E; Boutros-Toni F; Ly K; Loustaud-Ratti V; Soria P; Vidal E
    J Rheumatol; 2003 Jun; 30(6):1272-6. PubMed ID: 12784402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial.
    Mazlumzadeh M; Hunder GG; Easley KA; Calamia KT; Matteson EL; Griffing WL; Younge BR; Weyand CM; Goronzy JJ
    Arthritis Rheum; 2006 Oct; 54(10):3310-8. PubMed ID: 17009270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Giant cell arteritis and normal sedimentation rate: more than an exception!].
    von Blotzeim SG; Borruat FX
    Klin Monbl Augenheilkd; 1996 May; 208(5):397-9. PubMed ID: 8766063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis.
    Hernández-Rodríguez J; Segarra M; Vilardell C; Sánchez M; García-Martínez A; Esteban MJ; Queralt C; Grau JM; Urbano-Márquez A; Palacín A; Colomer D; Cid MC
    Rheumatology (Oxford); 2004 Mar; 43(3):294-301. PubMed ID: 14679293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism.
    Hernández-Rodríguez J; Segarra M; Vilardell C; Sánchez M; García-Martínez A; Esteban MJ; Grau JM; Urbano-Márquez A; Colomer D; Kleinman HK; Cid MC
    Circulation; 2003 May; 107(19):2428-34. PubMed ID: 12742994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients.
    Chevalet P; Barrier JH; Pottier P; Magadur-Joly G; Pottier MA; Hamidou M; Planchon B; El Kouri D; Connan L; Dupond JL; De Wazieres B; Dien G; Duhamel E; Grosbois B; Jego P; Le Strat A; Capdeville J; Letellier P; Agron L
    J Rheumatol; 2000 Jun; 27(6):1484-91. PubMed ID: 10852275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of serum interleukin-8 levels in patients with Behcet's disease: high levels may indicate vascular involvement.
    Durmazlar SP; Ulkar GB; Eskioglu F; Tatlican S; Mert A; Akgul A
    Int J Dermatol; 2009 Mar; 48(3):259-64. PubMed ID: 19261013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homocysteine levels in polymyalgia rheumatica and giant cell arteritis: influence of corticosteroid therapy.
    Martinez-Taboada VM; Bartolome MJ; Fernandez-Gonzalez MD; Blanco R; Rodriguez-Valverde V; Lopez-Hoyos M
    Rheumatology (Oxford); 2003 Sep; 42(9):1055-61. PubMed ID: 12730520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes.
    Proven A; Gabriel SE; Orces C; O'Fallon WM; Hunder GG
    Arthritis Rheum; 2003 Oct; 49(5):703-8. PubMed ID: 14558057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study.
    Salvarani C; Cantini F; Niccoli L; Catanoso MG; Macchioni P; Pulsatelli L; Padula A; Olivieri I; Boiardi L
    J Rheumatol; 2003 Apr; 30(4):760-3. PubMed ID: 12672196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis.
    Narváez J; Bernad B; Roig-Vilaseca D; García-Gómez C; Gómez-Vaquero C; Juanola X; Rodriguez-Moreno J; Nolla JM; Valverde J
    Semin Arthritis Rheum; 2007 Aug; 37(1):13-9. PubMed ID: 17360027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of elevated serum interleukin-6 levels in rheumatoid arthritis: correlation with erythrocyte sedimentation rate or C-reactive protein.
    Cohick CB; Furst DE; Quagliata S; Corcoran KA; Steere KJ; Yager JG; Lindsley HB
    J Lab Clin Med; 1994 May; 123(5):721-7. PubMed ID: 8195678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.